Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - escitalopram oxalate, quantity: 25.551 mg/ml (equivalent: escitalopram, qty 20 mg/ml) - oral liquid, solution - excipient ingredients: sodium hydroxide; ethanol; purified water; propyl gallate; citric acid - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 25 mg - neoral is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. neoral has been used in combination with azathioprine and corticosteroids. neoral is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. neoral can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. neoral is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., puva, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. while rebound rarely occurs, most patients will experience relapse with neoral as with other therapies upon cessation of treatment. neoral is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive neoral. psoriasis patients who are treated with neoral should not receive concomitant puva or uvb therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive neoral. although no adequate and well-controlled studies have been completed in children, transplant recipients as young as one year of age have received neoral with no unusual adverse effects. the safety and efficacy of neoral treatment in children with juvenile rheumatoid arthritis or psoriasis below the age of 18 have not been established. in rheumatoid arthritis clinical trials with cyclosporine, 17.5% of patients were age 65 or older. these patients were more likely to develop systolic hypertension on therapy, and more likely to show serum creatinine rises ≥ 50% above the baseline after 3 to 4 months of therapy. clinical studies of neoral in transplant and psoriasis patients did not include a sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experiences have not identified differences in response between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 2.5 mg/ml - oral liquid, solution - excipient ingredients: saccharin sodium; propylene glycol; brilliant blue fcf; glacial acetic acid; flavour - tablets. most types of epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalised epilepsy, or to secondary generalisation of partial epilepsy. in adults all varieties of generalised epilepsy, (including myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial epilepsy (including psychomotor seizures). injection. intravenous use for status epilepticus only. note. efficacy by the intramuscular route has not need demonstrated.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 10 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; mannitol; sucralose; carmellose calcium - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; carmellose calcium; sucralose; mannitol - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: carmellose calcium; sucralose; mannitol; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 20 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; carmellose calcium; sucralose; microcrystalline cellulose; mannitol; magnesium stearate - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: povidone; sodium propyl hydroxybenzoate; purified water; sodium methyl hydroxybenzoate; xanthan gum; glycerol; monobasic sodium phosphate dihydrate; sodium hydroxide; hydrochloric acid; sorbitol solution (70 per cent) (crystallising) - treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 20 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; crospovidone; hyprolose; lactose monohydrate; purified talc; magnesium stearate; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; hyprolose; magnesium stearate; crospovidone; purified talc; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.